

PHARMACEUTICAL 2023











PHARMACEUTICAL 2023

**GERON CORP** 

Rank 303 of 446



The relative strengths and weaknesses of GERON CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GERON CORP compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 39% points. The greatest weakness of GERON CORP is the variable Liabilities, Current, reducing the Economic Capital Ratio by 36% points.

The company's Economic Capital Ratio, given in the ranking table, is -2.9%, being 46% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	180,246
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	76,694
Liabilities, Non-Current	33,883
Other Assets	9,536
Other Compr. Net Income	-46
Other Expenses	6,882
Other Liabilities	0
Other Net Income	3,531
Other Revenues	596
Property and Equipment	793
Research and Development	95,518
Selling, General and Administrative Expense	43,628

Output Variable	Value in 1000 USD
Assets	190,575
Liabilities	110,577
Expenses	146,028
Revenues	596
Stockholders Equity	79,998
Net Income	-141,901
Comprehensive Net Income	-141,924
Economic Capital Ratio	-2.9%

